Tackling CV Risk in T2DM

Introduction/Background

T2DM as a Risk Factor for CVD

Close Linkage Between T2DM and HF

December 2008 FDA Guidance on Evaluating CV Risk in New Antidiabetic Therapies for T2DM

SAVOR-TIMI, EXAMINE, TECOS: Topline Results

DPP-4 Inhibitors: Topline Clinical Trial Results

EMPA-REG Primary Outcome (3-Point MACE): CV Death, Nonfatal MI, or Nonfatal Stroke

EMPA-REG: Results for CV Death

EMPA-REG: Hospitalization for HF

EMPA-REG Microvascular Outcomes: Renal Protection

Why Did the DPP-4 CV Outcome Trials Conflict With Epidemiology-Based Expectations?

DPP-4 Inhibitors: CV Meta-Analyses Results

Results of SGLT2i Meta-Analysis

Potential Mechanisms for CV Benefit Associated With Empagliflozin

CV Benefit Associated With RAS Blockade

SGLT2 Inhibitors and Reduced Volume Overload

Potential Pathways Linking SGLT2 Inhibitors and Reduced Risk of Hospitalization for HF

SGLT2 Inhibitors: Kidney Damage and Other AEs

LEADER: Baseline Characteristics

LEADER: Primary Outcome Liraglutide vs Placebo

What Explains the Macro- and Microvascular Improvements Observed in LEADER?

GLP-1 RAs and Cardiac Function

LEADER: Time to First Renal Event -- Macroalbuminuria, Doubling of Serum Creatinine, ESRD, Renal Death

Intensive Glycemic Control Increased All-Cause Mortality (ACCORD)

LEADER: AEs Leading to Treatment Discontinuation

SUSTAIN-6 (Semaglutide): Primary Outcome Results

EMPA-REG Outcomes: Class Effect or Agent Specific?

EMPA-REG and LEADER Results and Treatment Guidelines

Summary and Conclusions

Abbreviations

Abbreviations (cont)

Abbreviations (cont)